non-small-cell lung cancer leading cause of cancer-related mortality in the us current therapies:...
TRANSCRIPT
![Page 1: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/1.jpg)
![Page 2: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/2.jpg)
Non-Small-Cell Lung Cancer
• Leading cause of cancer-related mortality in the US
• Current Therapies: – “Despite great efforts, only minor gains”
Traynor et al. 2004 – Combination of Chemo/Surgery/Radiotherapy:
Platinum Doublets favored, in combo with other chemo reagent.
• Future Therapies: 166 ongoing clinical trials– EGFR over expressed in 40 to 80 % of cancers
![Page 3: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/3.jpg)
Peptide Vaccine
• Phase I Study of EGFRvIII Peptide Vaccine With Sargramostim (GM-CSF) Versus Keyhole Limpet Hemocyanin as Adjuvant in Patients With EGFRvIII-Expressing Cancer
Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against
Established Intracerebral TumorsHeimberger et al. 2003
![Page 4: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/4.jpg)
Vaccine Based Immunotherapy to L523S
– Phase I: Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer. The vaccine regimen will consist of two fixed doses of recombinant DNA (pVAX/L523S) followed by two doses of recombinant adenovirus (Ad/L523S). The trial will evaluate the dose escalation of Ad/L523S through three cohorts of patients.
![Page 5: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/5.jpg)
EGFR Schematic
Sordella et al. 2004
![Page 6: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/6.jpg)
Gefitinib:
• Targeting the proliferative signals in cancer cells --> EGFR– 1) In-Vitro Proof of Concept
• ZD1839 Synthesized/Screened --1994-2001
– 2) Animal Models– Mouse Xenografts: Success Not Dependant on Level of Expression of
EGFR ---2002
– 3) Initial Clinical Trials: 2001-2• Limited Tox• Response in only 10-19% of chemo-refractory advanced NSCL cancers• R Bailey et al. 2003 --> EGFR Expression not an effective predictor of
response to gefitinib
– 4) Molecular explanation???
![Page 7: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/7.jpg)
![Page 8: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/8.jpg)
• Factors that favor Gefitinib sensitivity:– Woman– Non-Smoker– Japenese– Adenocarcinoma
» Paez et al. 2004
![Page 9: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/9.jpg)
![Page 10: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/10.jpg)
![Page 11: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/11.jpg)
A highly significant effect in sensitive patients
![Page 12: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/12.jpg)
So What are the Mutations?
• Extract DNA
• Amplify Gene of Interest (28 exons)
• PCR
• Sequence (Sense + Antisense)
![Page 13: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/13.jpg)
![Page 14: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/14.jpg)
![Page 15: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/15.jpg)
What do these mutations tell us?
• 1) Hypothesis: Improved stability for binding of ATP and Gefitinib– Modified ATP binding pocket.
• 2) Hypothesis: Mutation plays a key role in the development of this cancer.– Somatic– Heterozygous ---> Dominance– Sequenced 95 primary tumors, 108 cancer-derived cell
lines. No EGFR mutants
![Page 16: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/16.jpg)
![Page 17: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/17.jpg)
![Page 18: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/18.jpg)
What does this all mean?
• Marker for the success of gefitinib?– Is this a good clinical test?– If there is no toxicity, can you add drug on top of standard
therapy despite low probability of success?
• Why the insensitivity with W.T. gefitinib?– 1) Kinetics: Bioavailability poor, (KD too high)
• Find a better way to knock out Kinase
– 2) The Mutant Kinase is more important to the cancer, than the wild type.
• Overexpression does not mean functionality is key. In-vitro models have to be interpreted carefully.
![Page 19: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/19.jpg)
![Page 20: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/20.jpg)
Science, August 20th 2004.
![Page 21: Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor](https://reader035.vdocuments.us/reader035/viewer/2022062715/56649d885503460f94a6dbd0/html5/thumbnails/21.jpg)